Metformin vs sulfonylureas.
One question separates these drugs and predicts every difference between them: does the drug push insulin, or does it make existing insulin work better? Everything about hypoglycaemia, weight and treatment durability follows from the answer.
Sulfonylureas close the ATP-sensitive potassium channel on the beta cell, releasing insulin whether or not glucose is high, which is why they cause hypoglycaemia and weight gain. Metformin does not touch insulin secretion at all, so it does neither.
Metformin vs Sulfonylureas at a glance
| Property | Metformin | Sulfonylureas |
|---|---|---|
| Mechanism | Reduces hepatic glucose output, improves sensitivity | Closes K-ATP channel, releasing insulin |
| Glucose-dependent | Yes, no effect when glucose is normal | No, releases insulin regardless |
| Hypoglycaemia alone | Rare | Common |
| Weight | Neutral or slight loss | Gain |
| Main serious risk | Lactic acidosis in renal impairment | Severe, prolonged hypoglycaemia |
| Durability | Better sustained | Declines as beta cell function falls |
Why only one causes hypoglycaemia
Hypoglycaemia requires insulin to be higher than the glucose load justifies. A sulfonylurea closes the potassium channel directly, depolarising the beta cell and triggering insulin release independently of the glucose concentration, so insulin can be released when it is not needed. Metformin reduces hepatic gluconeogenesis and improves peripheral sensitivity without stimulating secretion, leaving the normal counter-regulatory system intact.
Why weight moves in opposite directions
Insulin is an anabolic hormone, so unearned insulin promotes storage and weight gain, and patients eating to prevent hypoglycaemia gain more. Metformin is weight neutral or produces modest loss, partly through reduced appetite. In a condition where weight is itself part of the pathology, that difference is not cosmetic.
Why sulfonylureas fade over time
A sulfonylurea depends on functioning beta cells to have insulin to release. Type 2 diabetes involves progressive beta cell decline, so the drug loses effect as the disease advances. Metformin works on tissues rather than on the beta cell, so its effect is better sustained. Hypoglycaemia risk also rises in older adults and in renal impairment, where the longer-acting agents accumulate.
Which one would the question pick?
Exams rarely ask what a drug does. They describe a patient and ask which of the two you would choose, so the scenarios below matter more than either drug monograph.
| Scenario | Pick | Why |
|---|---|---|
| First-line type 2 diabetes | Metformin | No hypoglycaemia, weight neutral and durable. |
| Metformin contraindicated by renal impairment | Sulfonylurea or another class | Metformin accumulates and raises lactic acidosis risk. |
| Rapid glucose lowering needed | Sulfonylurea | Acts faster than metformin, which titrates slowly. |
| Older adult living alone | Metformin | Avoids the hypoglycaemia risk that carries the most harm in this group. |
Traps that catch people on this pair
Assuming all oral agents cause hypoglycaemia
Only the insulin secretagogues do. Metformin, SGLT2 inhibitors and DPP-4 inhibitors carry little risk when used alone.
Missing the beta blocker interaction
A beta blocker masks the adrenergic warning signs of hypoglycaemia, which matters far more with a sulfonylurea than with metformin.
Common questions
What is the difference between metformin and sulfonylureas?
Sulfonylureas close the ATP-sensitive potassium channel on the beta cell, releasing insulin whether or not glucose is high, which is why they cause hypoglycaemia and weight gain. Metformin does not touch insulin secretion at all, so it does neither.
Why does metformin not cause hypoglycaemia?
It reduces hepatic glucose production and improves insulin sensitivity without stimulating insulin secretion, so insulin never rises above what the glucose load justifies and counter-regulation stays intact.
Why do sulfonylureas cause weight gain?
They release insulin regardless of glucose level, and insulin is anabolic, so it promotes storage. Patients also eat to prevent or treat hypoglycaemia, which adds further weight.
Why is metformin first-line in type 2 diabetes?
It lowers glucose without causing hypoglycaemia or weight gain, its effect is durable, and it has a long safety record. Its main limitation is accumulation in significant renal impairment.
Go deeper on the mechanism
A comparison only sticks once the shared mechanism underneath it does, because what separates two drugs is always a variation on something they have in common.
- Endocrine pharmacology questions — test the distinction under time
- How beta blockers mask hypoglycaemia
Other comparisons
Heparin vs Warfarin · Warfarin vs DOACs · Unfractionated heparin vs Enoxaparin · Propranolol vs Atenolol · Metoprolol vs Atenolol · Amlodipine vs Nifedipine · Furosemide vs Bendroflumethiazide · Spironolactone vs Eplerenone · All comparisons
Study aid only. This page is written for learning and examination practice. It is not medical advice, not clinical decision support, and must never be used to make a decision about a real patient. Always verify against your local formulary, the product literature and a qualified pharmacist. See our medical disclaimer.
Two drugs, one property apart.
PharmBit teaches the shared mechanism first, then the single difference that splits the pair. Free to download.
Free to download. Annual Pro: 7-day trial for eligible new subscribers.